Beleza, beleza, meu bróder. Pode mandar. 
Manda ver qu'eu vou acabar escrevendo um tratado - e ói que isto dá grana! - 
sobre drogas com a minha, com a nossa, com a vossa vasta equisperiência.

Muchas Gracias,

Maorrílio, El Plinta.

--- Em qui, 20/11/08, Oswaldo Ribeiro <[EMAIL PROTECTED]> escreveu:
De: Oswaldo Ribeiro <[EMAIL PROTECTED]>
Assunto: [becodalama] para conhecimento do pesquisador Maorrílio Plinta
Para: "BECODALAMA" <[email protected]>
Data: Quinta-feira, 20 de Novembro de 2008, 12:53










    
            

---------- Forwarded message ----------
From: Robert Karl Stonjek <[EMAIL PROTECTED] com.au>

Date: 2008/11/20
Subject: [Mind and Brain] News: Scientists are high on idea that marijuana 
reduces memory impairment
To: Mind and Brain <[EMAIL PROTECTED] ps.com>, Psychiatry-Research 
<psychiatry-research @yahoogroups. com>



















    
            


Scientists are high on idea that marijuana 
reduces memory impairment

The more research they do, the 
more evidence Ohio State University scientists find that specific elements of 
marijuana can be good for the aging brain by reducing inflammation there and 
possibly even stimulating the formation of new brain 
cells.

The research suggests that the development 
of a legal drug that contains certain properties similar to those in marijuana 
might help prevent or delay the onset of Alzheimer's disease. Though the exact 
cause of Alzheimer's remains unknown, chronic inflammation in the brain is 
believed to contribute to memory impairment. 

Any new drug's properties 
would resemble those of tetrahydrocannabino l, or THC, the main psychoactive 
substance in the cannabis plant, but would not share its high-producing 
effects. 
THC joins nicotine, alcohol and caffeine as agents that, in moderation, have 
shown some protection against inflammation in the brain that might translate to 
better memory late in life. 

"It's not that everything immoral is good 
for the brain. It's just that there are some substances that millions of people 
for thousands of years have used in billions of doses, and we're noticing 
there's a little signal above all the noise," said Gary Wenk, professor of 
psychology at Ohio State and principal investigator on the research. 


Wenk's work has already shown that a THC-like synthetic drug can improve 
memory in animals. Now his team is trying to find out exactly how it works in 
the brain. 

The most recent research on rats indicates that at least 
three receptors in the brain are activated by the synthetic drug, which is 
similar to marijuana. These receptors are proteins within the brain's 
endocannabinoid system, which is involved in memory as well as physiological 
processes associated with appetite, mood and pain response. 

This 
research is also showing that receptors in this system can influence brain 
inflammation and the production of new neurons, or brain cells. 

"When 
we're young, we reproduce neurons and our memory works fine. When we age, the 
process slows down, so we have a decrease in new cell formation in normal 
aging. 
You need those cells to come back and help form new memories, and we found that 
this THC-like agent can influence creation of those cells," said Yannick 
Marchalant, a study coauthor and research assistant professor of psychology at 
Ohio State. 

Marchalant described the research in a poster presentation 
Wednesday (11/19) at the Society for Neuroscience meeting in Washington, D.C. 


Knowing exactly how any of these compounds work in the brain can make it 
easier for drug designers to target specific systems with agents that will 
offer 
the most effective anti-aging benefits, said Wenk, who is also a professor of 
neuroscience and molecular virology, immunology and medical genetics. 


"Could people smoke marijuana to prevent Alzheimer's disease if the 
disease is in their family? We're not saying that, but it might actually work. 
What we are saying is it appears that a safe, legal substance that mimics those 
important properties of marijuana can work on receptors in the brain to prevent 
memory impairments in aging. So that's really hopeful," Wenk said. 

One 
thing is clear from the studies: Once memory impairment is evident, the 
treatment is not effective. Reducing inflammation and preserving or generating 
neurons must occur before the memory loss is obvious, Wenk said. 


Marchalant led a study on old rats using the synthetic drug, called 
WIN-55212-2 (WIN), which is not used in humans because of its high potency to 
induce psychoactive effects. 

The researchers used a pump under the skin 
to give the rats a constant dose of WIN for three weeks – a dose low enough to 
induce no psychoactive effects on the animals. A control group of rats received 
no intervention. In follow-up memory tests, in which rats were placed in a 
small 
swimming pool to determine how well they use visual cues to find a platform 
hidden under the surface of the water, the treated rats did better than the 
control rats in learning and remembering how to find the hidden platform. 


"Old rats are not very good at that task. They can learn, but it takes 
them more time to find the platform. When we gave them the drug, it made them a 
little better at that task," Marchalant said. 

In some rats, Marchalant 
combined the WIN with compounds that are known to block specific receptors, 
which then offers hints at which receptors WIN is activating. The results 
indicated the WIN lowered the rats' brain inflammation in the hippocampus by 
acting on what is called the TRPV1 receptor. The hippocampus is responsible for 
short-term memory. 

With the same intervention technique, the researchers 
also determined that WIN acts on receptors known as CB1 and CB2, leading to the 
generation of new brain cells – a process known as neurogenesis. Those results 
led the scientists to speculate that the combination of lowered inflammation 
and 
neurogenesis is the reason the rats' memory improved after treatment with WIN. 


The researchers are continuing to study the endocannabinoid system's 
role in regulating inflammation and neuron development. They are trying to zero 
in on the receptors that must be activated to produce the most benefits from 
any 
newly developed drug. 

What they already know is THC alone isn't the 
answer. 

"The end goal is not to recommend the use of THC in humans to 
reduce Alzheimer's," Marchalant said. "We need to find exactly which receptors 
are most crucial, and ideally lead to the development of drugs that 
specifically 
activate those receptors. We hope a compound can be found that can target both 
inflammation and neurogenesis, which would be the most efficient way to produce 
the best effects." 

Source: Ohio State University
http://www.physorg. com/news14632010 2.html
 
Posted by
Robert Karl 
Stonjek

      

    
    
        
        
        
        


        


        
        
        
        
        




-- 
                                                 ÿØÿà

                                                    Ørf

"Não mostre para os outros o endereço eletrônico de seus amigos. Use Cco ou Bcc 
(cópia oculta)

 
Retire os endereços dos amigos antes de reenviar. Dificulte a disseminação de 
vírus, spams, hoaxes e banners."



      

    
    
        
         
        
        








        


        
        


      Veja quais são os assuntos do momento no Yahoo! +Buscados
http://br.maisbuscados.yahoo.com

Responder a